2 transcripts
SLRN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
. A substantial majority of our R&D expense, approximately 75%, is related to izokibep program, where we have been executing 3 Phase III programs this year in PsA
SLRN
Earnings call transcript
NASDAQ
2023 Q2
14 Aug 23
is an inflammation of the strong, dense, poorly vascular tissues that anchor our ligaments and tendons to bone. Enthesitis impacts the majority of moderate
- Prev
- 1
- Next